07:00 , Jun 29, 2015 |  BC Week In Review  |  Company News

amp biosimilars deal

amp granted an undisclosed Chinese pharma exclusive rights to commercialize ABY-021 in China. The humanized mAb is a biosimilar of an undisclosed compound in preclinical development for immunological indications. amp said the companies will...